Lasting Benefit for Stress Mgmt Post Breast Cancer Surgery

This article originally appeared here.
Share this content:
Lasting Benefit for Stress Mgmt Post Breast Cancer Surgery
Lasting Benefit for Stress Mgmt Post Breast Cancer Surgery

TUESDAY, March 24, 2015 (HealthDay News) -- For women with early-stage breast cancer, cognitive-behavioral stress management (CBSM) delivered after surgery is associated with long-term psychological benefits, according to a study published online March 23 in Cancer.

Noting that group-based CBSM delivered after surgery for early-stage breast cancer correlated with improved quality of life (QOL) over a 12-month follow-up and fewer depressive symptoms over five years, Jamie M. Stagl, from Massachusetts General Hospital/Harvard Medical School in Boston, and colleagues conducted an eight- to 15-year follow-up. Women with stage 0 to IIIb breast cancer were recruited after breast surgery and randomized to 10 weeks of CBSM or a one-day psychoeducational control. One hundred women (51 CBSM patients and 49 controls) were contacted again at eight to 15 years after study enrollment.

The researchers found that after adjustment for covariates, participants in the CBSM group reported significantly lower depressive symptoms (d, 0.63) and better QOL (d, 0.58).

"Women who received CBSM after surgery for early-stage breast cancer reported lower depressive symptoms and better QOL than the control group up to 15 years later," the authors write. "Early implementation of cognitive-behavioral interventions may influence long-term psychosocial functioning in breast cancer survivors."

One author disclosed receiving royalties from a book and related training material he had authored on CBSM treatments in health psychology.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths